PubMed Health⌕ Search

PubMed · 11122302

Thyroid stimulating hormone increases angiogenic growth factor expression in rat thyrocytes

Abstract

INTRODUCTION: Goitrogenesis is thought to be due to hyperstimulation of the thyroid stimulating hormone (TSH) receptor and is associated with dramatic andiogenesis within the thyroid. The angiogenic growth factors, fibroblast growth factor (FGF-2) and its receptor (FGFR-1) as well as Tie-2 (the receptor for the angiopoietins) are elevated in both the human goitre and in rat goitre. We have investigated the role of TSH in the expression of FGF-2, FGFR-1 and Tie-2 in FRTL-5 cells, which are a functional rat thyroid cell line. METHODS: Cells were cultured in medium containing 5% serum, insulin and antibodies and exposed to a variety of experimental conditions. Proteins were separated by electrophoresis and analysed by Western blotting using polyclonal antibodies to FGFR-1 (extracellular domain, Santa Cruz), Tie-2 (Santa Cruz) and FGF-2 (Sigma). RESULTS: TSH increased expression of FGF-2 reaching a maximum at 0.3 mU/ml returning to control levels at higher concentrations. A dominant fragment of its receptor (FGFR-1) at >> 57 kDa was dose-dependently increased by TSH. Tie-2 was thought to be predominantly expressed on endothelial cells but we now show that it is expressed as a full-length receptor on FRTL-5 cells with maximal expression at 0.3 mU/ml. This regulation is mediated by cAMP as forskolin and 8-Bromo-cAMP also increased Tie-2 expression. CONCLUSION: Both FGF-2 and its receptor, as well as Tie-2 are increased in rat thyroid cells by elevated TSH. These mechanisms may be central to the angiogenesis that occurs in goitrogenesis, and alteration of these growth factors may lead to new treatments for goitre.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

HC Cocks, JD Ramsden, JC Watkinson, MC Eggo. 2000. Thyroid stimulating hormone increases angiogenic growth factor expression in rat thyrocytes. https://doi.org/10.1046/j.1365-2273.2000.00422-10.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗